Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Latest COVID-19 wave less damaging for emerging market stocks

Published 05/07/2021, 02:12 AM
Updated 05/07/2021, 03:06 AM
© Reuters. FILE PHOTO: Drivers stand near auto rickshaw ambulances, prepared to transfer people suffering from the coronavirus disease (COVID-19) and their relatives for free, in New Delhi, India May 5, 2021.   REUTERS/Adnan Abidi

By Tom Arnold and Marc Jones

LONDON (Reuters) - Huge COVID-19 outbreaks in India, Brazil and Turkey have put developing economies at the epicentre of the pandemic, but their reluctance to fully lock down combined with hopes of vaccine progress globally appear to be desensitizing markets.

A move on Wednesday by the United States to back giving poorer countries access to vaccine blueprints has been widely welcomed - but it won't immediately close the widening gap in their rollout compared with developed nations.

Brazil, India and Mexico are among the five countries with the highest death rates from coronavirus, and low-income countries are estimated to need $200 billion over five years to battle the pandemic.

Vaccine rollouts are only just beginning in China, India, Russia, South Africa and Brazil, with the latter making the most progress with around 14% of its population now having received at least one dose of vaccine.

But there are only limited signs of the patchy rollout, or the wider battle against the pandemic, roiling equity markets.

MSCI's benchmark EM stocks index, which spans 27 countries, is up 48% over the past year, a similar level to the broader gauge of world stocks, including the United States where nearly half of the population has received at least one dose of vaccine.

In comparison, during the initial wave of the virus in 2020, $2.2 trillion was shaved off the overall value of MSCI's country emerging market share index.

Since then, they've surged by $4 trillion.

Investors have also gradually moved back into emerging equities, putting in $14.2 billion in April after pulling out a combined $83 billion from EM equity and bond markets at the peak of the panic in March 2020, according to the Institute of International Finance.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Graphic: Emerging market stocks bounced back from initial COVID slump, https://fingfx.thomsonreuters.com/gfx/mkt/jbyvryjzzpe/Pasted%20image%201620295745208.png

India, at the eye of the COVID-19 storm recently, has seen its market rise 5% year to date, even as it grapples with more than 21 million infections and has so far given only around 10% of its population at least one jab.

"From an investment perspective on India, the overall view that I have is that it's transitory," said Edward Evans, portfolio manager, emerging markets equity at Ashmore Group.

"The policy stance has been very proactive, has been very supportive and together with keeping expansionary monetary policy, that provides a very supportive liquidity backdrop that underpins some visibility on how earnings could unfold, and therefore, enables you as an investor to build conviction of how that can play out."

Graphic: Limited correlation between EM stocks and vaccination rates, https://fingfx.thomsonreuters.com/gfx/mkt/xlbvgaggrvq/Capture.PNG

VACCINE RELIEF

With less fiscal resources to splurge than their richer peers, many emerging central banks are expected to remain relatively cautious to ensure fragile economic recoveries take root.

Unlike during the first wave of the virus, investors can take comfort in the more imminent prospect that inoculation drives will eventually yield success.

Signs of encouragement emerged this week. U.S. President Joe Biden gave his support to waiving intellectual property rights for COVID-19 vaccines, and the leaders of the world's 20 largest economies will commit for the first time to fully fund a World Health Organization scheme to distribute vaccines and drugs to poorer nations.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Even so, the world still needs another 3 billion doses to reach 60% herd immunity this year, said Simon Quijano-Evans, Gemcorp Capital's chief economist.

And unlike the sweeping lockdowns during 2020 that prompted sharp downturns in economic activity, governments this time are generally opting for more targeted measures. India's government, for example, has resisted calls for a fresh nationwide lockdown, but several states have imposed social curbs.

"In general, EM economies have become a little less sensitive to incidence rates because governments haven't locked down or effectively people have had to go to work to eat," said Deutsche Bank (DE:DBKGn)'s Oliver Harvey.

Graphic: EM lockdowns are less severe during the latest wave, https://fingfx.thomsonreuters.com/gfx/mkt/ygdpzoqqavw/Capture.PNG

Latest comments

Author has visualized Imaginary Situation of India whereas Indian Residents are facing worst Situation in Decades. Prior to Pandemic atleast one of the Family Member was in Job. No there is One Family Member our of 5 Row Houses is in Job. All others have either no options or they are selling on Streets to feed their families anyhow. Selling on Streets is also banned since it is Lock Down which is extended every 5 Days. We are in Worst Situation than 2020 since One out of 5 is facing Covid symptoms and all Hospitals are full from April 21. There is Oxygen crisis too.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.